News

INTEGRIS Health announced it is among the first hospitals in the United States and the first hospital in Oklahoma to use, CCMTM therapy, delivered by the Optimizer® system, to treat patients suffering from heart failure.

$50 Heart Scan

INTEGRIS Health First in Oklahoma to Treat Heart Failure Patients Using Breakthrough CCM Therapy

INTEGRIS Health announced it is among the first hospitals in the United States and the first hospital in Oklahoma to use, CCMTM therapy, delivered by the Optimizer® system, to treat patients suffering from heart failure. Heart failure is a progressive condition with debilitating symptoms that can severely limit the quality of life for heart failure patients.

CCM therapy, also known as cardiac contractility modulation, is a new FDA-approved heart failure treatment proven to improve quality of life for patients who are no longer adequately responding to medications to manage symptoms, or to slow the progression of heart failure. The innovative therapy is the first of its kind intended to improve the contraction of the heart, allowing more oxygen-rich blood to reach the body.1 CCM therapy delivers precisely timed electrical pulses to the heart that are intended to improve the heart’s ability to contract and can be used in conjunction with medications and other heart failure therapies. 

The first patient treated in Oklahoma with CCM therapy was treated by Terrance Khastgir, M.D. on Jan. 29, 2021.

“CCM therapy is a breakthrough therapy option for heart failure patients that is intended to help them feel better, so they can start doing the things they love again,” said Khastgir. “Medications are not always enough to help slow the progression of heart failure and improve the quality of life for these patients. CCM therapy brings hope to this patient population by improving the often-debilitating symptoms of heart failure.” 

Heart failure, a condition in which the heart slowly weakens and is not able to adequately supply oxygen-rich blood, affects an estimated 6.5 million Americans and nearly 26 million people worldwide. By 2030, it is expected to affect 8 million Americans.

Heart failure patients experience debilitating symptoms, including breathlessness, fatigue, confusion and swelling in the legs that make everyday activities challenging and significantly diminish their quality of life. Today, most heart failure patients are prescribed medications intended to slow the progression of the disease and manage their symptoms. As the condition progresses, these treatments lose their effectiveness and the quality of life for heart failure patients will continue to decline.

CCM therapy may be an appropriate option for up to 70-percent of NYHA Class III (a classification of heart symptoms) heart failure patients who continue to experience symptoms despite taking the optimal heart failure medications for their condition.1 

CCM therapy was developed by Impulse Dynamics, based in Mount Laurel, NJ. Visit www.Impulse-Dynamics.Com to learn more about the company.  

 

Three Ways To Visit

We are ready to give you and your family the best care and that means we're introducing new safety guidelines for in-person visits and telehealth options.